These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 22682985

  • 1. 3D tumour spheroids as a model to assess the suitability of [18F]FDG-PET as an early indicator of response to PI3K inhibition.
    Kelly CJ, Hussien K, Muschel RJ.
    Nucl Med Biol; 2012 Oct; 39(7):986-92. PubMed ID: 22682985
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake.
    Monazzam A, Razifar P, Ide S, Rugaard Jensen M, Josephsson R, Blomqvist C, Langström B, Bergström M.
    Nucl Med Biol; 2009 Apr; 36(3):335-42. PubMed ID: 19324279
    [Abstract] [Full Text] [Related]

  • 3. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
    Maynard J, Emmas SA, Ble FX, Barjat H, Lawrie E, Hancox U, Polanska UM, Pritchard A, Hudson K.
    PLoS One; 2017 Apr; 12(8):e0183048. PubMed ID: 28806782
    [Abstract] [Full Text] [Related]

  • 4. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V.
    Clin Cancer Res; 2011 Aug 15; 17(16):5322-32. PubMed ID: 21712451
    [Abstract] [Full Text] [Related]

  • 5. Early changes in [18F]FDG incorporation by breast cancer cells treated with trastuzumab in normoxic conditions: role of the Akt-pathway, glucose transport and HIF-1α.
    Fleming IN, Andriu A, Smith TA.
    Breast Cancer Res Treat; 2014 Apr 15; 144(2):241-8. PubMed ID: 24522376
    [Abstract] [Full Text] [Related]

  • 6. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363.
    Maynard J, Ricketts SA, Gendrin C, Dudley P, Davies BR.
    Mol Imaging Biol; 2013 Aug 15; 15(4):476-85. PubMed ID: 23344784
    [Abstract] [Full Text] [Related]

  • 7. Selective PI3K inhibition by BKM120 and BEZ235 alone or in combination with chemotherapy in wild-type and mutated human gastrointestinal cancer cell lines.
    Mueller A, Bachmann E, Linnig M, Khillimberger K, Schimanski CC, Galle PR, Moehler M.
    Cancer Chemother Pharmacol; 2012 Jun 15; 69(6):1601-15. PubMed ID: 22543857
    [Abstract] [Full Text] [Related]

  • 8. Regulation of glucose uptake in lymphoma cell lines by c-MYC- and PI3K-dependent signaling pathways and impact of glycolytic pathways on cell viability.
    Broecker-Preuss M, Becher-Boveleth N, Bockisch A, Dührsen U, Müller S.
    J Transl Med; 2017 Jul 19; 15(1):158. PubMed ID: 28724379
    [Abstract] [Full Text] [Related]

  • 9. Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.
    O'Halloran PJ, Viel T, Murray DW, Wachsmuth L, Schwegmann K, Wagner S, Kopka K, Jarzabek MA, Dicker P, Hermann S, Faber C, Klasen T, Schäfers M, O'Brien D, Prehn JH, Jacobs AH, Byrne AT.
    Eur J Nucl Med Mol Imaging; 2016 Aug 19; 43(9):1673-83. PubMed ID: 26975402
    [Abstract] [Full Text] [Related]

  • 10. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models.
    Cullinane C, Dorow DS, Jackson S, Solomon B, Bogatyreva E, Binns D, Young R, Arango ME, Christensen JG, McArthur GA, Hicks RJ.
    J Nucl Med; 2011 Aug 19; 52(8):1261-7. PubMed ID: 21764800
    [Abstract] [Full Text] [Related]

  • 11. Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging.
    Schnell CR, Stauffer F, Allegrini PR, O'Reilly T, McSheehy PM, Dartois C, Stumm M, Cozens R, Littlewood-Evans A, García-Echeverría C, Maira SM.
    Cancer Res; 2008 Aug 15; 68(16):6598-607. PubMed ID: 18701483
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H, Jin X, Zhang Z, Xing Y, Kong X.
    Cell Biochem Funct; 2013 Jul 15; 31(5):427-33. PubMed ID: 23086777
    [Abstract] [Full Text] [Related]

  • 13. Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922.
    Bergstrom M, Monazzam A, Razifar P, Ide S, Josephsson R, Langstrom B.
    J Nucl Med; 2008 Jul 15; 49(7):1204-10. PubMed ID: 18552146
    [Abstract] [Full Text] [Related]

  • 14. Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
    Cullinane C, Waldeck KL, Binns D, Bogatyreva E, Bradley DP, de Jong R, McArthur GA, Hicks RJ.
    Nucl Med Biol; 2014 Feb 15; 41(2):148-54. PubMed ID: 24332383
    [Abstract] [Full Text] [Related]

  • 15. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F.
    Gynecol Oncol; 2015 Jul 15; 138(1):165-73. PubMed ID: 25933683
    [Abstract] [Full Text] [Related]

  • 16. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer.
    Monazzam A, Josephsson R, Blomqvist C, Carlsson J, Långström B, Bergström M.
    Breast Cancer Res; 2007 Jul 15; 9(4):R45. PubMed ID: 17659092
    [Abstract] [Full Text] [Related]

  • 17. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma.
    Kirstein MM, Boukouris AE, Pothiraju D, Buitrago-Molina LE, Marhenke S, Schütt J, Orlik J, Kühnel F, Hegermann J, Manns MP, Vogel A.
    Liver Int; 2013 May 15; 33(5):780-93. PubMed ID: 23489999
    [Abstract] [Full Text] [Related]

  • 18. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, Neyret A, Pannetier M, Willems L, Park S, Macone A, Maira SM, Ifrah N, Dreyfus F, Herault O, Lacombe C, Mayeux P, Bouscary D.
    Clin Cancer Res; 2010 Nov 15; 16(22):5424-35. PubMed ID: 20884625
    [Abstract] [Full Text] [Related]

  • 19. [18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy.
    Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, Wahl R, Endres C, Jimeno A, Pomper MG, Hidalgo M.
    J Clin Oncol; 2009 Jun 01; 27(16):2697-704. PubMed ID: 19380450
    [Abstract] [Full Text] [Related]

  • 20. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X, Zhao M, Hao M, Sun X, Wang J, Mao Y, Zu L, Liu J, Shen Y, Wang J, Shen K.
    Mol Cancer Res; 2013 Oct 01; 11(10):1269-78. PubMed ID: 23814023
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.